CONCORDBIO - IntraDay Trade Analysis with Live Signals

Last Updated Time : 05 Nov 25, 7:43 am

IntraDay Trade Rating: 2.8

📉 Oversold technicals and solid fundamentals offer a potential bounce setup, but weak momentum and volume limit intraday conviction.

📈 Positive

• 💰 Zero debt — strong financial stability.
• 📊 ROCE (28.4%) and ROE (21.4%) — efficient capital utilization.
• 📈 DII holding increased by 0.70% — domestic investor support improving.
• 📉 Trading near 52-week low — potential technical rebound zone.

⚠️ Limitation

• 📉 MACD at -44.6 and RSI at 37.2 — bearish momentum and weak buying strength.
• 📉 Volume significantly below average (20.8K vs 51K) — low intraday participation.
• 📉 Trading below DMA 50 and DMA 200 — confirms short-term and long-term downtrend.
• 📉 P/E of 42.6 vs industry P/E of 33.1 — trades at a premium despite recent weakness.

📰 Company Negative News

• 📉 FII holding dropped by 1.07% — foreign investor sentiment weakening.
• 📉 PAT declined from ₹142 Cr. to ₹42.6 Cr. — 26.9% quarterly contraction.

🌟 Company Positive News

• 📈 EPS of ₹34.2 and dividend yield of 0.74% — decent shareholder returns.

🧬 Industry

• 🧪 Operates in biopharma — long-term growth sector driven by innovation and global healthcare demand.
• 📊 Industry P/E of 33.1 — CONCORDBIO trades at a premium, reflecting past growth expectations.

📌 Conclusion

• 📉 Weak intraday setup with poor momentum and low volume, but oversold RSI may attract tactical buyers.
• 💡 Optimal buy range: ₹1,445–₹1,455. Target exit: ₹1,470–₹1,485.
• 🛑 Stop-loss: ₹1,430 to manage downside risk.
• 📤 If already holding, consider exiting near ₹1,470 if RSI crosses 42 or MACD flattens intraday.

I can also help you compare CONCORDBIO’s setup with other biopharma stocks showing stronger RSI and volume recovery patterns.